Trials / Recruiting
RecruitingNCT05714072
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
A Phase I Study of Ruxolitinib Plus Abemaciclib for Patients With Primary or Post-polycythemia Vera/Essential Thrombocythemia Myelofibrosis
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being done to see if the combination of ruxolitinib and abemaciclib is a safe and effective treatment for people with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | 10mg BID or 15mg BID |
| DRUG | Abemaciclib | 50, 100 and 150 mg |
Timeline
- Start date
- 2023-01-25
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
- First posted
- 2023-02-06
- Last updated
- 2025-11-18
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05714072. Inclusion in this directory is not an endorsement.